— Know what they know.
Not Investment Advice

AKRO NASDAQ

Akero Therapeutics, Inc.
1W: +0.3% 1M: +1.1% 3M: +26.4% 1Y: +84.0% 3Y: +20.2% 5Y: +93.0%
$54.65
Last traded 2025-12-09 — delisted
NASDAQ · Healthcare · Biotechnology · $4.5B mcap · 71M float · 3.60% daily turnover · Short 26% of daily vol

Balance Sheet Trends

Total Assets
$826M +42.3% ▲
5Y CAGR: +43.0%
Total Liabilities
$76M +68.5% ▲
5Y CAGR: +51.8%
Shareholders Equity
$750M +40.1% ▲
5Y CAGR: +42.3%
Cash & Investments
$743M +35.1% ▲
5Y CAGR: +40.4%
Total Debt
$36M +37.3% ▲
5Y CAGR: +236.1%
Net Debt
-$304M -46.1% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$187M$150M$250M$234M$340M
Short-Term Investments$81M$38M$102M$316M$403M
Cash & ST Investments$268M$188M$351M$550M$743M
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$0$0$0$10M$27M
Total Current Assets$271M$194M$355M$560M$770M
Property, Plant & Equip.$2M$2M$1M$1M$755K
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$19M$55M
Other Non-Current Assets$201K$417K$108K$0$0
Total Non-Current Assets$2M$2M$1M$20M$56M
Total Assets$273M$196M$357M$580M$826M
— Liabilities —
Accounts Payable$3M$7M$8M$7M$9M
Short-Term Debt$0$0$0$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$495K$554K$10M$1M$1M
Total Current Liabilities$13M$25M$19M$19M$40M
Long-Term Debt$0$0$10M$25M$35M
Other Non-Current Liab.$0$0$305K$54K$194K
Total Non-Current Liabilities$2M$1M$11M$26M$36M
Total Liabilities$15M$26M$30M$45M$76M
— Equity —
Common Stock$4K$4K$5K$6K$7K
Retained Earnings-$210M-$310M-$422M-$574M-$826M
Accumulated OCI-$3K-$27K$37K$270K$948K
Total Stockholders Equity$259M$169M$327M$535M$750M
Total Liabilities & Equity$273M$196M$357M$580M$826M
— Key Metrics —
Total Debt$2M$2M$11M$26M$36M
Net Debt-$185M-$149M-$239M-$208M-$304M
Total Investments$81M$38M$102M$335M$458M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms